BioNTech and Pfizer have joined forces to develop the former's mRNA-based influenza vaccines. Under the terms of the deal, BioNTech will receive upfront and near-term research payments totaling $120 million, plus milestone payments and royalties.
Scientists at the King Abdullah University of Science and Technology examined nitrogen oxide emissions from alcohol fuels such as ethanol and found that these fuels produce lower nitrogen oxide and greenhouse gas emissions compared with conventional fossil fuels.
AngioDynamics has paid an undisclosed amount for Surgical Specialties' BioSentry tract sealant system, which is designed for minimizing the occurrence of a common CT-guided percutaneous lung biopsy complication, pneumothorax, or collapsed lung.
AdvaMed has welcomed GE Healthcare as a member, and the company's president and CEO of imaging, Tom McGuinness, will serve on the association's board of directors. With the membership, GE will gain access to thought leadership and policy expertise, while "AdvaMed will benefit from the resources and expertise GE has built up over decades on the forefront of innovation and patient care," said Andrew Steiner, vice president of membership and business development for AdvaMed.
An offering of convertible senior notes due 2023 is expected to generate approximately $650 million for Illumina and could bring in up to $750 million if a 30-day option is exercised by initial purchasers to buy more notes. Net proceeds will be used for general corporate purposes and repurchasing up to $150 million of its stock along with the offering in private transactions.
A previously announced public offering of around 16.2 million shares of common stock has been priced by ViewRay at $9.25 each in hopes of raising $150 million in gross proceeds. Net proceeds from the offering, which includes an over-allotment option for underwriters to buy about 2.43 million shares, will be used as working capital and for general corporate purposes.
Terumo BCT announced that David Perez will retire from his position as president, CEO and member of the board of directors. Executive Vice President Antoinette Gawin will assume the roles of president on Oct. 1 and CEO on April 1.
The MolecuLight i:X, a device developed by MolecuLight for wound surface area assessment and pathogenic bacteria visualization, has been granted de novo clearance by the FDA. The system, which uses videos and still images in real time to capture fluorescence, is indicated for use as a hand-held imaging tool in point-of-care skin wound diagnosis and treatment.
In the 1940s, the randomized clinical trial began to replace real-world evidence, which had been used for centuries to discover treatments and cures, and though the transformation improved scientific rigor, it also devalued and diminished the use of evidence generated from clinicians' observations, write FDA Center for Drug Evaluation and Research Director Janet Woodcock and colleagues. The pendulum has since swung back to center as scientists realize the value of real-world data, and the FDA is developing scientifically valid ways to use RWD in drug development and review, they write.